AbbVie and EvolveImmune Therapeutics Collaborate on Next-Generation Cancer Biotherapeutics Using T-Cell Engager Technology

Collaboration Agreement:
AbbVie and EvolveImmune Therapeutics have entered into a collaboration and option-to-license agreement to develop next-generation cancer biotherapeutics using EvolveImmune's proprietary T-cell engager EVOLVE platform.

Platform Technology:
The EVOLVE platform is designed to deliver potent, selective, and integrated T-cell co-stimulation to enhance the tumor-killing capacity of T cells, addressing the limitations of current immunotherapies in solid and hematologic malignancies.

Financial Terms:
EvolveImmune will receive $65 million in aggregate upfront fees and equity investment from AbbVie, with the potential to receive up to $1.4 billion in aggregate option fees and milestones, as well as tiered royalty payments on net sales.

Oncology Expertise:
The partnership combines AbbVie's oncology expertise with EvolveImmune's T-cell engager technology to develop multispecific biologics for multiple targets in oncology.

Clinical Potential:
The collaboration aims to develop novel antibody-based therapies that can bypass low tumor immunogenicity, conditionally activate adaptive immunity, and reduce T-cell dysfunction, offering clinically meaningful benefits for patients with resistant cancer cells.